Celgene International Sárl Release: Studies Evaluating REVLIMID® (Lenalidomide) In Lymphoma Presented At American Society of Hematology
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.
Help employers find you! Check out all the jobs and post your resume.